IMMU.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$8M	+27.2%	$-1.51	$-1.58–$-1.43	—	3
2027	$172M	+2155.5%	$-0.73	$-1.13–$-0.19	—	3
2028	$8M	-95.4%	$-2.97	$-2.97–$-2.97	—	1
2029	$0	-100.0%	$-6.10	$-6.10–$-6.10	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-20	$-0.44	$-0.33	+24.4%
2026-02-11	$-0.83	$-0.74	+10.9%
2025-11-13	$-0.66	$-0.37	+43.8%
2025-08-21	$-0.83	$-0.45	+45.8%
2025-05-06	$-0.54	$-0.61	-13.5%
2025-02-13	$-0.72	$-0.63	+12.5%
2024-11-08	$-0.70	$-0.46	+34.3%

DCF fair valuemodel estimate

Intrinsic value

$0.80

Price

$6.50

Implied downside

-88%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
IMMU.STMendus AB (publ)	$6.50	-2.11%	$398M	—
ACE.STAscelia Pharma AB (publ)	$0.60	-3.54%	$80M	—
CLBIO.STCorline Biomedical AB	$15.15	-0.33%	$396M	—
ELIC.STElicera Therapeutics AB (publ)	$2.90	-2.35%	$194M	—
ISOFOL.STIsofol Medical AB (publ)	$0.71

Mendus AB (publ)

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.

www.mendus.com

Employees: 19
IPO / List date: Apr 22, 2013
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds IMMU.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in IMMU.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded IMMU.ST yet.